309 related articles for article (PubMed ID: 22319201)
1. NMS-P937, an orally available, specific small-molecule polo-like kinase 1 inhibitor with antitumor activity in solid and hematologic malignancies.
Valsasina B; Beria I; Alli C; Alzani R; Avanzi N; Ballinari D; Cappella P; Caruso M; Casolaro A; Ciavolella A; Cucchi U; De Ponti A; Felder E; Fiorentini F; Galvani A; Gianellini LM; Giorgini ML; Isacchi A; Lansen J; Pesenti E; Rizzi S; Rocchetti M; Sola F; Moll J
Mol Cancer Ther; 2012 Apr; 11(4):1006-16. PubMed ID: 22319201
[TBL] [Abstract][Full Text] [Related]
2. Targeting polo-like kinase 1 by NMS-P937 in osteosarcoma cell lines inhibits tumor cell growth and partially overcomes drug resistance.
Sero V; Tavanti E; Vella S; Hattinger CM; Fanelli M; Michelacci F; Versteeg R; Valsasina B; Gudeman B; Picci P; Serra M
Invest New Drugs; 2014 Dec; 32(6):1167-80. PubMed ID: 25193492
[TBL] [Abstract][Full Text] [Related]
3. NMS-P937, a 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivative as potent and selective Polo-like kinase 1 inhibitor.
Beria I; Bossi RT; Brasca MG; Caruso M; Ceccarelli W; Fachin G; Fasolini M; Forte B; Fiorentini F; Pesenti E; Pezzetta D; Posteri H; Scolaro A; Re Depaolini S; Valsasina B
Bioorg Med Chem Lett; 2011 May; 21(10):2969-74. PubMed ID: 21470862
[TBL] [Abstract][Full Text] [Related]
4. The Polo-Like Kinase 1 (PLK1) inhibitor NMS-P937 is effective in a new model of disseminated primary CD56+ acute monoblastic leukaemia.
Casolaro A; Golay J; Albanese C; Ceruti R; Patton V; Cribioli S; Pezzoni A; Losa M; Texido G; Giussani U; Marchesi F; Amboldi N; Valsasina B; Bungaro S; Cazzaniga G; Rambaldi A; Introna M; Pesenti E; Alzani R
PLoS One; 2013; 8(3):e58424. PubMed ID: 23520509
[TBL] [Abstract][Full Text] [Related]
5. TAK-960, a novel, orally available, selective inhibitor of polo-like kinase 1, shows broad-spectrum preclinical antitumor activity in multiple dosing regimens.
Hikichi Y; Honda K; Hikami K; Miyashita H; Kaieda I; Murai S; Uchiyama N; Hasegawa M; Kawamoto T; Sato T; Ichikawa T; Cao S; Nie Z; Zhang L; Yang J; Kuida K; Kupperman E
Mol Cancer Ther; 2012 Mar; 11(3):700-9. PubMed ID: 22188812
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Polo-like kinase 1 causes growth reduction and apoptosis in pediatric acute lymphoblastic leukemia cells.
Hartsink-Segers SA; Exalto C; Allen M; Williamson D; Clifford SC; Horstmann M; Caron HN; Pieters R; Den Boer ML
Haematologica; 2013 Oct; 98(10):1539-46. PubMed ID: 23753023
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.
Klauck PJ; Bagby SM; Capasso A; Bradshaw-Pierce EL; Selby HM; Spreafico A; Tentler JJ; Tan AC; Kim J; Arcaroli JJ; Purkey A; Messersmith WA; Kuida K; Eckhardt SG; Pitts TM
BMC Cancer; 2018 Feb; 18(1):136. PubMed ID: 29402316
[TBL] [Abstract][Full Text] [Related]
8. Polo-like kinase 1 inhibitor NMS-P937 represses nasopharyngeal carcinoma progression via induction of mitotic abnormalities.
Gao J; Huang W; Zhao S; Wang R; Wang Z; Ye J; Lin L; Cai W; Mi Y
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23590. PubMed ID: 38037286
[TBL] [Abstract][Full Text] [Related]
9. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors.
Zhang M; Singh R; Peng S; Mazumdar T; Sambandam V; Shen L; Tong P; Li L; Kalu NN; Pickering CR; Frederick M; Myers JN; Wang J; Johnson FM
Cancer Lett; 2017 Apr; 392():71-82. PubMed ID: 28126323
[TBL] [Abstract][Full Text] [Related]
10. Synergistic apoptotic effect of miR-183-5p and Polo-Like kinase 1 inhibitor NMS-P937 in breast cancer cells.
Kudo M; Zalles N; Distefano R; Nigita G; Veneziano D; Gasparini P; Croce CM
Cell Death Differ; 2022 Feb; 29(2):407-419. PubMed ID: 34561554
[TBL] [Abstract][Full Text] [Related]
11. The GSK461364 PLK1 inhibitor exhibits strong antitumoral activity in preclinical neuroblastoma models.
Pajtler KW; Sadowski N; Ackermann S; Althoff K; Schönbeck K; Batzke K; Schäfers S; Odersky A; Heukamp L; Astrahantseff K; Künkele A; Deubzer HE; Schramm A; Sprüssel A; Thor T; Lindner S; Eggert A; Fischer M; Schulte JH
Oncotarget; 2017 Jan; 8(4):6730-6741. PubMed ID: 28036269
[TBL] [Abstract][Full Text] [Related]
12. A novel treatment strategy targeting polo-like kinase 1 in hematological malignancies.
Ikezoe T; Yang J; Nishioka C; Takezaki Y; Tasaka T; Togitani K; Koeffler HP; Yokoyama A
Leukemia; 2009 Sep; 23(9):1564-76. PubMed ID: 19421227
[TBL] [Abstract][Full Text] [Related]
13. Targeting the mitotic checkpoint for cancer therapy with NMS-P715, an inhibitor of MPS1 kinase.
Colombo R; Caldarelli M; Mennecozzi M; Giorgini ML; Sola F; Cappella P; Perrera C; Depaolini SR; Rusconi L; Cucchi U; Avanzi N; Bertrand JA; Bossi RT; Pesenti E; Galvani A; Isacchi A; Colotta F; Donati D; Moll J
Cancer Res; 2010 Dec; 70(24):10255-64. PubMed ID: 21159646
[TBL] [Abstract][Full Text] [Related]
14. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
[TBL] [Abstract][Full Text] [Related]
15. Small molecule inhibition of polo-like kinase 1 by volasertib (BI 6727) causes significant melanoma growth delay and regression in vivo.
Cholewa BD; Ndiaye MA; Huang W; Liu X; Ahmad N
Cancer Lett; 2017 Jan; 385():179-187. PubMed ID: 27793694
[TBL] [Abstract][Full Text] [Related]
16. Identification of 4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors.
Beria I; Ballinari D; Bertrand JA; Borghi D; Bossi RT; Brasca MG; Cappella P; Caruso M; Ceccarelli W; Ciavolella A; Cristiani C; Croci V; De Ponti A; Fachin G; Ferguson RD; Lansen J; Moll JK; Pesenti E; Posteri H; Perego R; Rocchetti M; Storici P; Volpi D; Valsasina B
J Med Chem; 2010 May; 53(9):3532-51. PubMed ID: 20397705
[TBL] [Abstract][Full Text] [Related]
17. Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer.
Giordano A; Liu Y; Armeson K; Park Y; Ridinger M; Erlander M; Reuben J; Britten C; Kappler C; Yeh E; Ethier S
PLoS One; 2019; 14(11):e0224420. PubMed ID: 31751384
[TBL] [Abstract][Full Text] [Related]
18. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1.
Lansing TJ; McConnell RT; Duckett DR; Spehar GM; Knick VB; Hassler DF; Noro N; Furuta M; Emmitte KA; Gilmer TM; Mook RA; Cheung M
Mol Cancer Ther; 2007 Feb; 6(2):450-9. PubMed ID: 17267659
[TBL] [Abstract][Full Text] [Related]
19. Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis.
Gilmartin AG; Bleam MR; Richter MC; Erskine SG; Kruger RG; Madden L; Hassler DF; Smith GK; Gontarek RR; Courtney MP; Sutton D; Diamond MA; Jackson JR; Laquerre SG
Cancer Res; 2009 Sep; 69(17):6969-77. PubMed ID: 19690138
[TBL] [Abstract][Full Text] [Related]
20. ER maleate is a novel anticancer agent in oral cancer: implications for cancer therapy.
Fu G; Somasundaram RT; Jessa F; Srivastava G; MacMillan C; Witterick I; Walfish PG; Ralhan R
Oncotarget; 2016 Mar; 7(13):17162-81. PubMed ID: 26934445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]